WO2009011420A1 - Therapeutic agent for type-2 diabetes - Google Patents

Therapeutic agent for type-2 diabetes Download PDF

Info

Publication number
WO2009011420A1
WO2009011420A1 PCT/JP2008/063008 JP2008063008W WO2009011420A1 WO 2009011420 A1 WO2009011420 A1 WO 2009011420A1 JP 2008063008 W JP2008063008 W JP 2008063008W WO 2009011420 A1 WO2009011420 A1 WO 2009011420A1
Authority
WO
WIPO (PCT)
Prior art keywords
type
therapeutic agent
diabetes
act
liver
Prior art date
Application number
PCT/JP2008/063008
Other languages
French (fr)
Japanese (ja)
Inventor
Shinichi Ishii
Muneshige Shiraishi
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Priority to JP2009523682A priority Critical patent/JPWO2009011420A1/en
Publication of WO2009011420A1 publication Critical patent/WO2009011420A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Disclosed is a medicinal agent comprising ursodeoxycholic acid or a pharmacologically acceptable salt thereof as an active ingredient, which can be act as a therapeutic agent for type-2 diabetes accompanied by fatty liver or liver dysfunction.
PCT/JP2008/063008 2007-07-18 2008-07-18 Therapeutic agent for type-2 diabetes WO2009011420A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009523682A JPWO2009011420A1 (en) 2007-07-18 2008-07-18 Treatment for type 2 diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-186430 2007-07-18
JP2007186430 2007-07-18

Publications (1)

Publication Number Publication Date
WO2009011420A1 true WO2009011420A1 (en) 2009-01-22

Family

ID=40259746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063008 WO2009011420A1 (en) 2007-07-18 2008-07-18 Therapeutic agent for type-2 diabetes

Country Status (2)

Country Link
JP (1) JPWO2009011420A1 (en)
WO (1) WO2009011420A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013041519A1 (en) * 2011-09-19 2013-03-28 ETH Zürich, ETH Transfer Ror gamma modulators
CN115137732A (en) * 2021-03-29 2022-10-04 中国科学院大连化学物理研究所 GPR120 receptor agonist and application of ursodeoxycholic acid

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BONDINI, S. ET AL.: "Non-alcoholic fatty liver disease and hepatitis C infection", MINERVA GASTROENTEROL DIETOL, vol. 52, no. 2, 2006, pages 135 - 143, XP002663026 *
ITOH, S. ET AL.: "Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis", DIG DIS SCI, vol. 48, no. 11, 2003, pages 2182 - 2186 *
LINDOR, K.D. ET AL.: "Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial", HEPATOLOGY, vol. 39, no. 3, 2004, pages 770 - 778, XP002663026 *
MARCHESINI, G. ET AL.: "Nonalcoholic fatty liver disease and the metabolic syndrome", MINERVA CARDIOANGIOL, vol. 54, no. 2, 2006, pages 229 - 239 *
OZCAN, U. ET AL.: "Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes", SCIENCE, vol. 313, August 2006 (2006-08-01), pages 1137 - 1140, XP002674360 *
SASS, D.A. ET AL.: "Nonalcoholic fatty liver disease: a clinical review", DIG DIS SCI, vol. 50, no. 1, 2005, pages 171 - 180, XP019237111 *
TOLMAN, K.G. ET AL.: "Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease", DIABETES CARE, vol. 30, no. 3, March 2006 (2006-03-01), pages 734 - 743, XP055354115 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013041519A1 (en) * 2011-09-19 2013-03-28 ETH Zürich, ETH Transfer Ror gamma modulators
KR20140079416A (en) * 2011-09-19 2014-06-26 에테하 쭈리히 Ror gamma modulators
AU2012311599B2 (en) * 2011-09-19 2017-07-06 Eth Zurich Ror gamma modulators
RU2658013C2 (en) * 2011-09-19 2018-06-19 Этх Цюрих Ror-gamma modulators
KR102020923B1 (en) 2011-09-19 2019-09-11 에테하 쭈리히 Ror gamma modulators
CN115137732A (en) * 2021-03-29 2022-10-04 中国科学院大连化学物理研究所 GPR120 receptor agonist and application of ursodeoxycholic acid

Also Published As

Publication number Publication date
JPWO2009011420A1 (en) 2010-09-24

Similar Documents

Publication Publication Date Title
WO2010122980A8 (en) NOVEL THYROID HORMONE β RECEPTOR AGONIST
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2011051354A3 (en) Transdermal pharmaceutical compositions comprising active agents
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
EP2196206B8 (en) Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
WO2005089718A3 (en) Pharmaceutical compositions
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2008096001A8 (en) Hcv inhibiting macrocyclic phenylcarbamates
WO2011066980A3 (en) Oral dosage forms with reduced potential for drug abuse
WO2009051119A1 (en) Pyrimidyl indoline compound
WO2009004082A3 (en) Anticonvulsive pharmaceutical compositions
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
SI1932522T1 (en) Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient
EP2045253A4 (en) alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
WO2010130773A3 (en) Benzoxazolone derivatives as aldosterone symthase inhibitors
TN2012000092A1 (en) Therapeutic agent for mood disorders
MY163762A (en) Therapeutic agent for chronic renal failure
WO2012140596A8 (en) Glycoside derivatives and uses thereof
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2008068299A3 (en) Hydrobromide salt of an anti-hiv compound
WO2011047837A3 (en) Melt-granulated cinacalcet
EP2316420A8 (en) Method to reduce pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791317

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009523682

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791317

Country of ref document: EP

Kind code of ref document: A1